Navigation Links
Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
Date:11/13/2008

SAN DIEGO, Nov. 13, 2008 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Lazard Capital Markets Healthcare Conference in New York on Wednesday, November 19, 2008 at 8:30 a.m. ET. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will be providing a corporate overview.

The live presentation will be Web cast, and a recording will be made available following the event. The Web cast and recording will be accessible through Amylin's corporate Web site, located at http://www.amylin.com. To access the live Web cast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Lilly and Amylin Set Date and Time for Conference Call
2. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
3. Amylin Pharmaceuticals Reports First Quarter Financial Results
4. Amylin Pharmaceuticals Reports 2007 Financial Results
5. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
6. Amylin Pharmaceuticals to Present at Research & Development Day
7. Amylin Pharmaceuticals to Webcast Conference Call
8. Amylin Pharmaceuticals to Webcast Third Quarter Results
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. MiddleBrook Pharmaceuticals Reports Third Quarter 2008 Financial Results
11. MAP Pharmaceuticals Reports Third Quarter of 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... (PRWEB) , ... March 30, 2017 , ... ... host the live audio conference “ Preventing Hospital Readmissions Through Discharge Planning ” ... 2017 at 1:00 pm ET. This conference discusses strategies to prevent readmissions in ...
(Date:3/29/2017)... ... ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today that Rhino Ag has named ... more than 650 U.S.-based dealers. Rhino, a member of the Alamo Group, offers a ... cutters, rear blades, post hole diggers, pasture renovators, tillers, disc mowers and box blades. ...
(Date:3/29/2017)... Atlanta, Georgia (PRWEB) , ... March 29, 2017 , ... ... Theresa Therilus, founder of Pet Protect Law that assists dog owners in ... will assist new owners in taking the natural next step to protect their new ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) ... and feedback from high school and college students who have participated in the program ... 7-23 and YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... several educational opportunities for attending prescribers at the upcoming World Congress, in Hollywood ... “A4M has always been recognized as the visionary leader in the training of ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... PHILADELPHIA , March 30, 2017  Lannett Company, ... the company voluntarily made a $25 million payment against ... $25 million payment, combined with the $75 million payment ... us approximately $5.5 million in annualized cash interest expense, ... executive officer of Lannett.  "Our business is solid and ...
(Date:3/30/2017)... Revenue Prospects by Product Type (Metered Dose ... Geography Respiratory Inhalers - our new study reveals trends, ... market heading? If you are involved in this sector you must ... the potential revenues streams to 2027, assessing data, trends, opportunities and ... ...
(Date:3/30/2017)... Julie & Lefkowitz LLP, a class action law firm dedicated ... fiduciary duty claim involving the board of directors of Synergy ... If you are a shareholder of Synergy Pharmaceuticals and are ... charge, please visit us at: ... http://pjlfirm.com/synergy-pharmaceuticals-inc/ ...
Breaking Medicine Technology: